TheTechno Optimist.

EnhertuDaiichi Sankyo—Enhertu plus pertuzumab approved in the US as first-line treatment for HER2-positive metastatic breast cancerDatrowayDaiichi Sankyo—Datroway approved in the US for first-line triple-negative breast cancer after extending survivalEnhertuDaiichi Sankyo—FDA approves Enhertu for early HER2-positive breast cancer, both before and after surgery

Enhertu

by Daiichi SankyoJP

Deliver chemotherapy straight into HER2-bearing cancer cells so far more drug reaches the tumour and less the rest of the body, and move that benefit from late-stage disease to the first treatment patients get.

ScalingStage 5 of 5

Approved in 5 cancer types; added first-line HER2+ (Dec 2025) and early breast cancer (May 2026).

Updated 15 May 2026Checked 11 Oct0 updates this week

Milestones

No announced next step
  1. AstraZeneca partnership signedMar 2019Complete.
  2. FDA: first drug for HER2-low breast cancer (DESTINY-Breast04)5 Aug 2022Complete.
  3. FDA: first-line HER2+ metastatic, with pertuzumab (DESTINY-Breast09)Dec 2025Complete.
  4. FDA: early HER2+ breast cancer before and after surgery15 May 2026Complete.

Most important updates

Primer